New pill takes on tough blood cancers in early trial
NCT ID NCT04775745
First seen Feb 22, 2026 · Last updated Jun 19, 2026 · Updated 19 times
Summary
This early-phase study is testing an experimental oral drug called LP-168 in about 60 people with several types of B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to find the safest dose and to see how the drug behaves in the body. Researchers will also look for signs that the drug is shrinking tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Duke Univerisity
RECRUITINGDurham, North Carolina, 27708, United States
-
Huntsman Cancer Institute, University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
-
Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
-
University of Cincinnati
RECRUITINGCincinnati, Ohio, 45221, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LP-168 (an oral small molecule inhibitor)
What this could lead to
If it works, this could point toward a new treatment option for people with certain blood cancers that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 60 participants, so it is primarily testing safety and dosing. The drug may not work well or could have serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.